Diabetes drug dapagliflozin tested to shield hearts during breast cancer treatment

NCT ID NCT07070765

Recruiting now Disease control Sponsor: University of Aberdeen Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether dapagliflozin, a diabetes drug, can prevent heart damage caused by anthracycline chemotherapy in breast cancer patients. About 70 women aged 18-70 with low to medium heart risk will take either dapagliflozin or standard care during their chemo. The goal is to see if the drug helps keep the heart's energy levels healthy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dapagliflozin (a diabetes drug that may protect the heart)
What this could lead to: If it works, this could point toward a way to prevent heart damage in breast cancer patients receiving chemotherapy.
What could go wrong: This is a small, early-phase study (70 people) testing a drug not yet proven for this use. It may not show a clear benefit, and side effects from dapagliflozin are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Cardiac Research Office, Aberdeen Royal Infirmary
RECRUITING

Aberdeen, Aberdeenshire, AB25 2ZD, United Kingdom
University of Aberdeen
RECRUITING

Aberdeen, AB25 2ZD, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.